New treatment approaches for prostate cancer based on peptide analogues

European Urology
Anton StangelbergerBob Djavan

Abstract

New therapy modalities for the treatment of advanced prostate cancer based on peptide analogues are reviewed. Agonists and antagonists of luteinising hormone-releasing hormone (LHRH) lead to androgen deprivation, but direct effects on tumours may also play a role. Radiolabeled somatostatin analogues can be targeted to tumours expressing receptors for somatostatin and have been successfully applied for the localization of these tumours. Tumoural LHRH, growth hormone-releasing hormone (GHRH), and bombesin/gastrin-releasing peptide (BN/GRP) and their receptors appear to be involved in the proliferation of prostate cancer. On the basis of the recent advances in the understanding of the role of neuropeptides in tumour growth and progression, new therapeutic modalities are being developed that are based on antagonists of GHRH and of BN/GRP, which inhibit growth factors or their receptors. Another promising approach for the therapy of prostate cancer consists of the use of cytotoxic analogues of LHRH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in prostate cancers and their metastases. New promising forms of hormone therapy and targeted chemotherapy may improve therapy of advanced stage prostate c...Continue Reading

References

Jul 1, 1992·The Journal of Clinical Endocrinology and Metabolism·P LimontaM Motta
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·G TolisA V Schally
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M KovacsK Groot
Jun 1, 1997·Journal of Endocrinological Investigation·Y C Patel
Jul 27, 1999·The Prostate·N J HegartyD S Coffey
Nov 5, 1999·Trends in Endocrinology and Metabolism : TEM·A V Schally, J L Varga
Oct 12, 2000·The Prostate·A V SchallyZ Rekasi
Oct 6, 2001·Frontiers in Neuroendocrinology·A V SchallyG Halmos
Mar 20, 2002·Nature Reviews. Cancer·B J Feldman, D Feldman
Oct 5, 2002·The Journal of Clinical Endocrinology and Metabolism·Gabor HalmosZoltan Rekasi
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Randall MillikanChristopher J Logothetis
Jan 27, 2004·The Prostate·Samuel R Denmeade, John T Isaacs
Jul 9, 2005·International Journal of Cancer. Journal International Du Cancer·Anton StangelbergerRobert Vessella
Nov 18, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anton StangelbergerCelia A Kanashiro
Nov 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Alexandre HavtCelia A Kanashiro
Aug 15, 2006·Current Treatment Options in Oncology·Rebecca A Moss, Daniel P Petrylak
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith

❮ Previous
Next ❯

Citations

Jan 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ferenc G RickAndrew V Schally
Nov 24, 2011·Prostate Cancer·Kristene Myklak, Shandra Wilson
Jan 15, 2013·Journal of Amino Acids·Jyothi Thundimadathil
Jan 1, 2009·Cancer Management and Research·Shandra Wilson
Dec 21, 2012·Future Oncology·Guillaume Ploussard, Pierre Mongiat-Artus
Jan 1, 2014·Proceedings of the National Academy of Sciences of the United States of America·Miklos JaszberenyiAndrew V Schally
Aug 5, 2009·Expert Opinion on Emerging Drugs·Kashif Siddiqui, Laurence H Klotz
Mar 10, 2012·Clinical Genitourinary Cancer·Deliu-Victor MateiOttavio de Cobelli
Jan 28, 2009·European Urology·Joery P F MolenaarArjen Hoogendam
Jan 19, 2008·European Urology·Aristotelis Bamias, Meletios A Dimopoulos
May 16, 2015·Peptides·Irene Ramos-ÁlvarezRobert T Jensen
Jul 11, 2012·International Journal of Cancer. Journal International Du Cancer·Laura Muñoz-MorenoAna M Bajo
Jun 14, 2015·Urologic Oncology·Takahiro KimuraShin Egawa
Apr 29, 2009·Methods : a Companion to Methods in Enzymology·R P J SchroederM de Jong
Sep 6, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Athanasios Dellis, Athanasios Papatsoris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.